文献速递脊柱关节炎

Guselkumab在活动性侵蚀性银屑病关节炎中持续抑制结构损伤进展并改善疾病活动:APEX研究48周结果

Sustained Inhibition of Structural Damage Progression and Improvements in Disease Activity With Guselkumab in Biologic-Naïve Participants with Active and Erosive Psoriatic Arthritis: Results Through Week 48 of the Phase 3b Randomized, Double-Blind, Placebo-Controlled APEX Study.
PubMed 文献 · Arthritis Rheumatol · 2026-10-20

APEX研究纳入1020例生物制剂初治的活动性侵蚀性银屑病关节炎患者,随机接受guselkumab每4周、每8周或安慰剂后换用guselkumab。至48周,guselkumab组ACR20/50/70应答率分别为71-74%/51-56%/31-35%,vdH-S评分最小二乘均值变化为0.60-0.78,60-64%达HAQ-DI临床意义改善,74-80%达PASI90,36-41%达MDA。安慰剂组换用guselkumab后结构损伤进展减缓且临床应答率提高。

要点

  • Guselkumab至48周维持ACR20/50/70应答率71-74%/51-56%/31-35%。
  • Guselkumab组vdH-S评分最小二乘均值变化0.60-0.78,结构损伤进展低。
  • 安慰剂换用guselkumab后vdH-S变化从0-24周0.96降至24-48周0.41。

核心结论

  • APEX研究48周结果支持guselkumab用于银屑病关节炎多种表现的持久全面治疗。
  • Guselkumab抑制累积关节损伤可能优化结局。

研究设计与样本

  • APEX为3b期随机双盲安慰剂对照研究,纳入1020例生物制剂初治活动性侵蚀性银屑病关节炎成人患者。
  • 患者随机接受guselkumab每4周(N=273)、guselkumab第0、4周后每8周(N=371)或安慰剂后第24周起换用guselkumab每4周(N=376)。

主要发现

  • 至48周,93%(950/1020)参与者完成研究干预。
  • Guselkumab每4周和每8周组至48周ACR20/50/70应答率分别为71-74%/51-56%/31-35%。
  • Guselkumab组vdH-S评分最小二乘均值变化为0.60-0.78。
  • 60-64%参与者报告HAQ-DI临床意义改善,74-80%达PASI90,36-41%达MDA。
  • 安慰剂组换用guselkumab后结构损伤进展减缓(vdH-S最小二乘均值变化第0-24周0.96;第24-48周0.41),临床应答率至48周提高。

关键数值与推荐

  • ACR20/50/70应答率使用多重/无应答者插补法计算。
  • 临床意义改善定义为HAQ-DI改善≥0.35分。
  • PASI90定义为银屑病面积和严重程度指数改善≥90%。
  • MDA为最小疾病活动度。

临床怎么用

  • Guselkumab可用于生物制剂初治的活动性侵蚀性银屑病关节炎患者,至48周持续抑制结构损伤进展并改善疾病活动。
  • 对安慰剂延迟治疗患者,换用guselkumab后结构损伤进展减缓且临床应答提高。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In APEX, guselkumab, which binds to the IL-23p19 subunit and CD64 on IL-23-producing cells, demonstrated significant joint efficacy and inhibition of structural damage progression in participants with active and erosive PsA through Week (W)24; W48 findings are reported herein. METHODS: The APEX modified full analysis set included 1020 biologic-naïve adults with active PsA (≥3 tender joints; ≥3 swollen joints; CRP ≥0.3mg/dL; ≥2 erosive joints) randomized to guselkumab every (Q)4W (N=273), guselkumab at W0,4 then Q8W (N=371), or placebo followed by guselkumab Q4W beginning at W24 (N=376). Outcomes through W48 included ACR20/50/70 response rates (using multiple/nonresponder imputation); least squares mean (LSM) change in PsA-modified van der Heijde-Sharp score (vdH-S); achievement of clinically meaningful improvement (CMI; ≥0.35-point) in HAQ-DI, ≥90% improvement in Psoriasis Area and Severity Index (PASI90), and minimal disease activity (MDA). RESULTS: Through W48, 93% (950/1020) of participants completed study intervention. Guselkumab Q4W and Q8W through W48 demonstrated durable ACR20/50/70 response rates (71-74%/51-56%/31-35%), and low rates of structural damage progression (vdH-S LSM change: 0.60-0.78); 60-64% of participants reported HAQ-DI CMI, 74-80% achieved PASI90, 36-41% achieved MDA. Following transition to guselkumab, structural damage progression among placebo-randomized participants diminished (vdH-S LSM change W0-24: 0.96; W24-48: 0.41) and clinical response rates increased through W48. Adverse event rates were consistent with placebo and guselkumab through W24 and stable through W48 of guselkumab. CONCLUSION: APEX W48 findings further support guselkumab use for durable and comprehensive treatment of diverse PsA manifestations. Inhibition of cumulative joint damage with guselkumab may optimize outcomes.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Ritchlin CT, Mease PJ, Coates LC, et al. Sustained Inhibition of Structural Damage Progression and Improvements in Disease Activity With Guselkumab in Biologic-Naïve Participants with Active and Erosive Psoriatic Arthritis: Results Through Week 48 of the Phase 3b Randomized, Double-Blind, Placebo-Controlled APEX Study. Arthritis Rheumatol. 2026. PMID: 42901870. doi:10.1002/art.70380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。